Peptide Stack · Research protocol
The GLP-1 + amylin + fat-oxidation stack
Semaglutide, cagrilintide, and AOD-9604 — the modern research protocol for maximum fat loss with muscle preservation.
Protocol goal
Sustained fat loss with reduced GI side effects and better appetite control than semaglutide alone.
Protocol timeline
Adults with BMI >27 seeking sustainable fat loss who have already tried diet + exercise alone. Research-use protocol.
Pregnancy, personal or family history of medullary thyroid carcinoma, MEN 2, active pancreatitis, or type 1 diabetes.
Frequently asked questions
Why stack cagrilintide with semaglutide?
Semaglutide targets GLP-1; cagrilintide targets amylin. Combining them hits two independent satiety pathways. Novo Nordisk's CagriSema Phase 3 trials showed 22.7% body weight reduction — nearly double sema alone.
What does AOD-9604 add?
AOD-9604 is the C-terminal fragment of human growth hormone. It stimulates lipolysis in adipose tissue without the IGF-1 elevation of full-length GH. Best for stubborn abdominal fat that resists caloric deficit.
How long is a typical run?
Research protocols run 16–24 weeks with dose titration. Sudden discontinuation typically produces appetite rebound; taper over 4 weeks.